Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Helena Linardou(Metropolitan Hospital), Issa J Dahabreh(National and Kapodistrian University of Athens), Dimitrios Bafaloukos(Metropolitan Hospital), P. Kosmidis(Hygeia Hospital), Samuel Murray(Metropolitan Hospital)
Nature Reviews Clinical Oncology
June 1, 2009
10.1038/nrclinonc.2009.62
Cited by 235Open Access
Full Text

Abstract

Related Papers

Untangling the ErbB signalling network
Yosef Yarden, Mark X. Sliwkowski|Nature Reviews Molecular Cell Biology|2001|6.9k
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al.|New England Journal of Medicine|2005|3.9k
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman et al.|Nature reviews. Cancer|2007|3.1k
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Ming‐Sound Tsao, Akira Sakurada, Jean-Claude Cutz et al.|New England Journal of Medicine|2005|1.9k
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi et al.|JNCI Journal of the National Cancer Institute|2005|1.6k